Ampyra Seizure Warnings Strengthened Followed Continued Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
The seizure risk for Acorda’s multiple sclerosis drug was already known, but an FDA MedWatch Alert based on post-market adverse event reports says, “the majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures.”